RxDoctor Payments Data

Monica Dua, MD

Internal Medicine · North Versailles, PANPI 1548224892

Payments from drug & device makers

$1,257in general payments, 2019–2025

Across 37 payments — averaging $33.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$230
  • Shockwave Medical, Inc$218
  • Edwards Lifesciences$201
  • AbbVie$148
  • Pfizer$99
  • Novo Nordisk$88
  • plus $272 from 8 others

What the payments were for

  • Food & beverage$1,257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,257 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$91,839
Medicare patients
283
Services billed
914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban381$201,146
JardianceEmpagliflozin113$117,521
JanuviaSitagliptin Phosphate78$61,541
TrulicityDulaglutide55$52,975
OzempicSemaglutide49$49,438
XareltoRivaroxaban61$43,384
TradjentaLinagliptin53$31,028
ProliaDenosumab15$26,373
MounjaroTirzepatide16$26,071
MyrbetriqMirabegron65$21,721
Breo ElliptaFluticasone/Vilanterol32$21,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,223
Repatha SureclickEvolocumab16$18,701
Combivent RespimatIpratropium/Albuterol Sulfate21$11,525
Atorvastatin Calcium919$10,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$201,146381 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat, Spiriva Respimat$16$167,501202 claims
Lilly USA, LLCTrulicity, Mounjaro$18$79,04671 claims
MerckJanuvia$21$61,54178 claims
Novo NordiskOzempic$88$49,43849 claims
GSKBreo Ellipta, Trelegy Ellipta$76$41,49759 claims
AmgenProlia$74$26,37315 claims
AbbVieSynthroid, Lumigan$148$8,624119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in North Versailles

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →